Selank has a notably clean interaction profile — no documented pharmacokinetic conflicts with commonly co-administered peptides. The interaction cautions that do exist relate to pharmacodynamic overlap: stacking Selank with other anxiolytic compounds risks additive CNS depression, and combining with stimulating peptides like Semax requires careful dose management.
What happens when Selank and Semax are combined?
Selank is anxiolytic and mildly sedating at higher doses; Semax is cognitively stimulating and can provoke restlessness at higher doses. In combination, users report that Selank moderates Semax's edge without eliminating its cognitive benefit — a pharmacodynamic balancing effect. This is mechanistically plausible: Selank's GABAergic modulation may buffer Semax's stimulating BDNF and dopaminergic effects. However, dose-finding is individual — the modulating effect is not uniform.
What is the anxiolytic overlap risk with other compounds?
Combining Selank with pharmaceutical anxiolytics (benzodiazepines, buspirone) or other GABAergic peptides risks additive CNS depression beyond what either compound alone produces. This is a pharmacodynamic concern, not a pharmacokinetic one — both can be present in the body without direct chemical interaction, but their combined effect on CNS depression is potentially greater than expected from dose calculation alone.